Middle East and Africa Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies and NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Bispecific Antibodies), Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, and Others), End User (Research & Academic Institutes, Hospitals, and Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, and Others)-Industry Trends and Forecast to 2030.
Middle East and Africa Natural Killer (NK) Cell Therapeutics Market Analysis and Insights
The Middle East and Africa natural killer (NK) cell therapeutics market comprises features such as the increasing need for better therapeutics options that will impact the launching of a new product by manufacturers into the market enhancing its demand as well as increasing investment in R&D leading to the market growth. Currently, various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative NK cell therapies, which is expected to provide various other opportunities for market growth. However, the lack of specificity and poor in-vivo survival of the cells, and the high cost associated with therapies are expected to restrain market growth in the forecast period.
The Middle East and Africa natural killer (NK) cell therapeutics market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyzes that the Middle East and Africa natural killer (NK) cell therapeutics market will grow at a CAGR of 40.8% during the forecast period of 2023 to 2030.
The Middle East and Africa natural killer (NK) cell therapeutics market report provides details of market share, new developments, product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief, our team will help you create a revenue-impact solution to achieve your desired goal.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in Million and Pricing in USD
|
|
Segments Covered
|
Therapeutics (NK Cell Therapies and NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Bispecific Antibodies), Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, and Others), End User (Research & Academic Institutes, Hospitals, and Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, and Others)
|
|
Countries Covered
|
Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and rest of Middle East and Africa
|
|
Market Players Covered
|
Bristol-Myers Squibb Company, Sanofi, and Takeda Pharmaceutical Company Limited among others
|
Market Definition
Natural killer (NK) cells are large granular lymphocytes that have the ability to quickly respond to a pathological challenge. They are important components of the innate immune system and play an important role in generating an immune response against malignancies and infectious diseases caused by viral pathogens. They have been recognized to induce the direct killing of targeted cells involving cancer cells. They have the ability to recognize the multitude of infected cells without being dependent on a single antigen-expressing cell.
NK cells secrete cytokines and chemokines that recruit other immune cells such as T cells and B cells, which enhances the immune response against the tumor cells. As NK cells do not express T cell receptors, they induce a low risk of graft-versus-host disease. Moreover, iPSC cell lines derived NK cell therapy that is CAR-NK therapy overcomes the need for a long and complex manufacturing process that allows patients with aggressive tumors to afford tumor treatment as soon as possible. Along with this iPSC derived NK cells can be infused repeatedly, which enhances the immune response with dose regulation.
Middle East and Africa Natural Killer (NK) Cell Therapeutics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
DRIVERS
- Increase in Patient Population with Chronic Diseases
Chronic diseases are diseases that generally occur in older adults that can be controlled but not cured such as heart disease, arthritis, diabetes, stroke, or cancer. They are a worldwide healthcare problem concern. The change in lifestyle along with physical inactivity, unhealthy diet, and tobacco use is increasing the burden of chronic diseases all over the world.
An increasing number of patients population with chronic diseases led the scientist and researchers to work on a new innovative therapeutic approach so as to provide patients with the best curative treatment option, which can be achieved by using NK cell therapy that has the potential to generate a strong immune response and has the anti-tumor capability as well.
- Rise in Awareness about Immunotherapies
As cancer is a devastating disease and available treatment options may cause the reoccurrence of tumors, the need for the best therapeutic approach is increasing day by day. Immunotherapies have attracted a lot of attention in recent years for the treatment of various types of malignancies. Among the immunotherapies, CAR–T cell therapies have been studied and were used as well but have several limitations, which led to the development of NK cell therapies. As a drug based on an NK cell therapeutic approach has not been approved yet, it thus needs to raise awareness among the population.
This is why several organizations and market players are launching a campaign to enhance awareness regarding NK cell therapies.
OPPORTUNITY
- Strategic Initiatives by Market Players
Various strategic initiatives are adopted by market players which involve expansion, acquisition, and collaboration among others. These initiatives help them to increase the company’s product portfolio leading to market expansion and hence enhancing the product demand among customers, which ultimately leads the players to earn maximum revenue.
As the demand for effective and affordable NK cell immunotherapy is increasing worldwide, these strategic initiatives are taken by top market players aimed at enhancing business operations and earning more profitability in the market.
RESTRAINT/CHALLENGE
- Lack of Specificity and Poor In Vivo Survival of the cells
Lack of specificity and poor in-vivo survival of NK cells poses a challenge in front of manufacturers dealing in the market. The lack of specificity of NK cells leads to targeting the wrong cells, which can lead to ineffective treatment. Along with this, the lack of specificity and poor in-vivo survival of NK cells also reduces the therapeutic effect of administered NK cell therapy.
Such problems decrease the credibility of therapy used in clinical trials and pose a challenge in front of manufacturers while getting approval.
Recent Developments
- In January 2022, Takeda acquired Adaptate biotherapeutics to develop novel gamma delta (γδ) T cell engager therapies targeting solid tumors. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are designed to specifically modulate γδ T cell-mediated immune responses at tumor sites while sparing damage to healthy cells. This acquisition helped the company to focus on R&D.
- In December 2021, Nektar Therapeutics announced phase 1b data for novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with atopic dermatitis. NKTR-358 is designed to treat autoimmune and inflammatory conditions by correcting the immune system imbalance that results from increased levels of inflammatory T cells and reduced numbers and impaired function of immune regulating Treg cells. This has helped the company to focus on R&D for further phases.
Middle East and Africa Natural Killer (NK) Cell Therapeutics Market Scope
The Middle East and Africa natural killer (NK) cell therapeutics market is segmented into five notable segments based on therapeutics, approaches, application, end-user, and distribution channel. The growth among these segments will help you analyze niche pockets of growth and strategies to approach the market and determine the core application areas and the difference in the target markets.
Therapeutics
- NK Cell Therapies
- NK Cell Directed Antibodies
Based on therapeutics, the market is segmented into NK cell therapies and NK cell directed antibodies.
Approaches
- Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
- Bispecific Antibodies
Based on approaches, the market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies.
Application
- Cancer
- Immunoproliferative Disorders
- Acute Infectious Diseases
- Gastrointestinal Diseases
- Others
Based on application, the market is segmented into cancer, immunoproliferative disorders, acute infectious diseases, gastrointestinal diseases, and others.
End User
- Research & Academic Institutes
- Hospitals
- Specialty Clinics
Based on end user, the market is segmented into hospitals, specialty clinics, and research & academic institutes.
Distribution Channel
- Hospital Pharmacies
- Direct Tender
- Others
Based on distribution channel, the market is segmented into hospital pharmacies, direct tender, and others.
Middle East and Africa Natural Killer (NK) Cell Therapeutics Market Regional Analysis/Insights
The Middle East and Africa natural killer (NK) cell therapeutics market is categorized into five notable segments: therapeutics, approaches, application, end-user, and distribution channel.
The countries covered in this market report are Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and rest of Middle East and Africa.
Saudi Arabia is dominating the Middle East and Africa natural killer (NK) cell therapeutics market.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and the challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Natural Killer (NK) Cell Therapeutics Market Share Analysis
The Middle East and Africa natural killer (NK) cell therapeutics market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the Middle East and Africa natural killer (NK) cell therapeutics market are Bristol-Myers Squibb Company, Sanofi, andTakeda Pharmaceutical Company Limited.
SKU-